title: Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
abstract: OBJECTIVE
  To identify factors associated with the use of single or dual antiplatelet therapy in patients prescribed warfarin following coronary stenting and to investigate whether single (aspirin or thienopyridine) vs. dual antiplatelet therapy plus warfarin leads to an excess of adverse outcomes.
  
  
  RESULTS
  We analysed data from 800 patients with an acute coronary syndrome who underwent coronary stenting (130 patients received a drug-eluting stent) and were discharged on warfarin and either dual (n = 580) or single (n = 220) antiplatelet therapy. The use of single antiplatelet therapy was more common in Europe than in the USA (34 vs. 17%, P < 0.001). There was no difference in major bleeding in hospital or in 6-month mortality or myocardial infarction. In the single antiplatelet group, the use of either aspirin or thienopyridine (clopidogrel or ticlopidine) in combination with warfarin resulted in similar outcomes.
  
  
  CONCLUSIONS
  Use of single vs. dual antiplatelet therapy and warfarin following stenting is common. In this observational study, there was no difference in mortality or myocardial infarction at 6 months; however, larger trials are needed to assert any firm recommendations.
authors.affiliation: Centre for Cardiovascular Therapeutics, Western Hospital, Melbourne, Australia. mcnguyen@bidmc.harvard.edu
authors.forename: Michael C
authors.initials: MC
authors.lastname: Nguyen
authors.forename: Yean L
authors.initials: YL
authors.lastname: Lim
authors.forename: Antony
authors.initials: A
authors.lastname: Walton
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Lefkovits
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Agnelli
authors.forename: Shaun G
authors.initials: SG
authors.lastname: Goodman
authors.forename: Andrzej
authors.initials: A
authors.lastname: Budaj
authors.forename: Dietrich C
authors.initials: DC
authors.lastname: Gulba
authors.forename: Jeanna
authors.initials: J
authors.lastname: Allegrone
authors.forename: David
authors.initials: D
authors.lastname: Brieger
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012044:Regression Analysis; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents; D016019:Survival Analysis; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin